JP Morgan Raises PT On Emergent BioSolutions To $35

Symbols: EBS
Share

JP Morgan has raised the price target on Emergent BioSolutions (NYSE: EBS) from $27 to $35 and maintains its Overweight rating.


 
 
< Previous
JP Morgan Lowers PT On BioMimetic Therapeutics To $10
Next >
Citi Reiterates Buy on Cerner Corporation, Raises PT to $152
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust